- Home
- BKE vs NAMS Comparison
BKE vs NAMS Comparison
Compare BKE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- NAMS
- Stock Information
- Founded
- BKE 1948
- NAMS 2019
- Country
- BKE United States
- NAMS Netherlands
- Employees
- BKE N/A
- NAMS N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- NAMS Health Care
- Exchange
- BKE Nasdaq
- NAMS Nasdaq
- Market Cap
- BKE 2.8B
- NAMS 3.1B
- IPO Year
- BKE 1992
- NAMS N/A
- Fundamental
- Price
- BKE $57.18
- NAMS $37.08
- Analyst Decision
- BKE Hold
- NAMS Strong Buy
- Analyst Count
- BKE 1
- NAMS 10
- Target Price
- BKE $54.00
- NAMS $44.80
- AVG Volume (30 Days)
- BKE 459.8K
- NAMS 1.2M
- Earning Date
- BKE 11-21-2025
- NAMS 11-05-2025
- Dividend Yield
- BKE 6.80%
- NAMS N/A
- EPS Growth
- BKE N/A
- NAMS N/A
- EPS
- BKE 4.00
- NAMS N/A
- Revenue
- BKE $1,250,675,000.00
- NAMS $35,243,000.00
- Revenue This Year
- BKE $7.09
- NAMS N/A
- Revenue Next Year
- BKE $2.91
- NAMS N/A
- P/E Ratio
- BKE $14.34
- NAMS N/A
- Revenue Growth
- BKE 1.62
- NAMS 4.91
- 52 Week Low
- BKE $33.12
- NAMS $14.06
- 52 Week High
- BKE $61.69
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- BKE 56.66
- NAMS 57.92
- Support Level
- BKE $53.93
- NAMS $35.42
- Resistance Level
- BKE $58.33
- NAMS $40.74
- Average True Range (ATR)
- BKE 1.38
- NAMS 2.19
- MACD
- BKE 0.38
- NAMS -0.32
- Stochastic Oscillator
- BKE 77.30
- NAMS 46.37
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.